Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Post-Transplant Complications

Causative factors for prolonged hospitalization beyond the point of engraftment in patients after autologous peripheral blood stem cell transplantation


In order to assess the incidence and analyze reasons which cause prolongation of hospital stay in patients engrafted after peripheral blood stem cell transplantation (PBSCT), we performed this retrospective analysis. One hundred patients (receiving 123 conditioning regimens) were included in the analysis. Criteria for discharge were presence of myeloid engraftment and absence of severe concomitant problems. Ninety subjects (73%) were discharged just after engraftment was reached on day +12 (10–14). Discharge was delayed in 33 patients (27%) and the mean prolongation was 3 days (1–11). In 31 patients (25%) delayed discharge was due to complications: in 14 patients (11.4%) because of GIT problems, in 16 patients (13%) because of infectious complications and in one patient because of cardiotoxicity. A significantly higher number of infectious complications was found in patients conditioned with BEAM (19.7% vs 4.2%, P < 0.05) while GIT toxicity was the most common reason for discharge delays in patients conditioned with melfalan 200 mg/m2 (8.2% vs 14.7%, NS). No risk factors of hospital stay prolongation were determined. We conclude that in spite of rapid engraftment, non-hematological toxicities and infections remain important limitations for further reduction of the length of patient hospitalization in a significant number of patients after PBSCT. Bone Marrow Transplantation (2000) 26, 877–880.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout


  1. Kessinger A, Armitage JO, Landmark JD et al. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic functions following marrow ablative therapy Blood 1988 71: 723–729

    CAS  PubMed  Google Scholar 

  2. McQuaker IG, Hunter AE, Pacey S et al. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit J Clin Oncol 1997 15: 451–457

    Article  CAS  Google Scholar 

  3. Nemunaitis J, Rabinowe SN, Singer JW et al. Recombinant granulocyte–macrophage colony-stimulating factor after autologous marrow transplantation for lymphoid cancer New Engl J Med 1991 324: 1773–1778

    Article  CAS  Google Scholar 

  4. Cetkovský P, Koza V, Jindra P et al. Individual criteria could be optimal for starting G-CSF application after autologous stem cell transplantation Bone Marrow Transplant 1997 20: 639–641

    Article  Google Scholar 

  5. Bolwell BJ, Pohlman B, Andresen S et al. Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial Bone Marrow Transplant 1998 21: 369–373

    Article  CAS  Google Scholar 

  6. Buijt I, Ossenkopele GJ, Uyl-de-Groot CA, Huijgens PC . Costs of intensive treatment and follow-up of patients with multiple myeloma Anti-Cancer Drugs 1998 9: 889–897

    Article  CAS  Google Scholar 

  7. Le Corroller AG, Moatti JP . The economic evaluation of hematopoietic growth factors in high dose chemotherapy Anti-Cancer Drugs 1998 9: 917–925

    Article  CAS  Google Scholar 

  8. Uyl-de Groot CA, Hijgens PC, Rutten FFH . Colony-stimulating factors and peripheral blood progenitor cell transplantation: benefits and costs PharmacoEconomics 1996 10: 23–35

    Article  CAS  Google Scholar 

  9. Klumpp TR, Mangan KF, Goldberg SL et al. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial J Clin Oncol 1995 13: 1323–1329

    Article  CAS  Google Scholar 

  10. Westermann AM, Holtkamp MJ, Linthorst GAM et al. At-home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies Ann Oncol 1999 10: 511–517

    Article  CAS  Google Scholar 

  11. Hartmann O, Le Corroller AG, Blaise D et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial Ann Intern Med 1997 126: 600–607

    Article  CAS  Google Scholar 

  12. Bensinger WI, Appelbaum FR, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells J Clin Oncol 1995 13: 2547–2555

    Article  CAS  Google Scholar 

  13. Peniket AJ, Perry AR, Linch DC, Goldstone AH . Delays in discharge from hospital after haematological recovery from peripheral blood stem cell transplantation: is recovery from gut toxicity an important factor? Bone Marrow Transplant 1997 19: (Suppl. 1) S 126 (Abstr. P 501)

    Google Scholar 

  14. Cetkovský P, Jindra P, Škopek P et al. Rapid engraftment does not shorten the duration of hospital stay in some patients after peripheral blood stem cell transplantations (PBSCT) Bone Marrow Transplant 1999 23: (Suppl. 1) S165 (Abstr. 544)

    Google Scholar 

  15. Jindra P, Koza V, Cetkovský P et al. Cyclophosphamide 3 g/m2 and G-CSF is an effective and safe outpatient-based PBSC mobilizing regimen: a single centre experience (letter) Bone Marrow Transplant 1997 20: 91–93

    Article  CAS  Google Scholar 

  16. Guba SC, Vesole DH, Jagannath S et al. Peripheral stem cell mobilization and engraftment in patients over age 60 Bone Marrow Transplant 1997 20: 1–3

    Article  CAS  Google Scholar 

  17. Haas R, Möhle R, Frühauf S et al. Patients characteristics associated with successful mobilization and autografting of peripheral blood progenitor cells in malignant lymphoma Blood 1994 83: 3787–3794

    CAS  PubMed  Google Scholar 

  18. Olivieri A, Corvatta L, Montanari M et al. Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells Bone Marrow Transplant 1998 21: 1049–1053

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cetkovský, P., Škopek, P. & Schützová, M. Causative factors for prolonged hospitalization beyond the point of engraftment in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 26, 877–880 (2000).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • peripheral blood stem cell transplantation (PBSCT)
  • cost-effectiveness
  • granulocyte colony stimulating factor (G-CSF)
  • hematopoietic reconstitution
  • non-hematological toxicity

This article is cited by


Quick links